Meeting
2019 Gastrointestinal Cancers Symposium
A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
Authors
Uwe Pelzer
Charité– Universitätsmedizin Berlin, Berlin, BS, Germany
Uwe Pelzer , Johanna C. Bendell , Mark S. Womack IV, Nathan Bahary , Erkut Hasan Borazanci , Donna Elise Levy , Gary Mo , Samuel Cowan Ramage , Ignacio Garrido-Laguna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03086369
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 330)
DOI
10.1200/JCO.2019.37.4_suppl.330
Abstract #
330
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.
First Author: Johanna C. Bendell
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
First Author: Wungki Park
Poster
2022 ASCO Annual Meeting
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
First Author: Wungki Park